Trial record 1 of 3 for: "Polycystic Liver Disease" | "Antifungal Agents"
Polycystic Liver Disease in Kidney Transplant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00934791|
Recruitment Status : Terminated (Terminated due to inadequate enrollment)
First Posted : July 8, 2009
Results First Posted : March 8, 2013
Last Update Posted : March 8, 2013
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
Patrick G. Dean, Mayo Clinic
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Polycystic Liver Disease
Drug: Mycophenolate Mofetil
|Recruitment Details||Two participants were enrolled in the study in Rochester, Minnesota. One participant withdrew before doing any part of the study; he was not randomized to a group.|
This study was terminated due to inadequate enrollment, no data was collected on the participant.